99 related articles for article (PubMed ID: 10570951)
1. Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor.
Drouet C; Bouillet L; Csopaki F; Colomb MG
FEBS Lett; 1999 Sep; 458(3):415-8. PubMed ID: 10570951
[TBL] [Abstract][Full Text] [Related]
2. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
Cai S; Davis AE
J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
[TBL] [Abstract][Full Text] [Related]
3. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
4. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
5. The regulation of human factor XIIa by plasma proteinase inhibitors.
Pixley RA; Schapira M; Colman RW
J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
[TBL] [Abstract][Full Text] [Related]
6. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
7. Identification of HIV-1 protease cleavage site in human C1-inhibitor.
Gerencer M; Burek V
Virus Res; 2004 Sep; 105(1):97-100. PubMed ID: 15325085
[TBL] [Abstract][Full Text] [Related]
8. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate.
Patston PA; Gettins P; Beechem J; Schapira M
Biochemistry; 1991 Sep; 30(36):8876-82. PubMed ID: 1888745
[TBL] [Abstract][Full Text] [Related]
10. Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide.
Urbani A; Biasiol G; Brunetti M; Volpari C; Di Marco S; Sollazzo M; Orrú S; Piaz FD; Casbarra A; Pucci P; Nardi C; Gallinari P; De Francesco R; Steinkühler C
Biochemistry; 1999 Apr; 38(16):5206-15. PubMed ID: 10213628
[TBL] [Abstract][Full Text] [Related]
11. Oxidative inactivation of purified human alpha-2-antiplasmin, antithrombin III, and C1-inhibitor.
Stief TW; Aab A; Heimburger N
Thromb Res; 1988 Mar; 49(6):581-9. PubMed ID: 2455361
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
Brower MS; Harpel PC
J Biol Chem; 1982 Aug; 257(16):9849-54. PubMed ID: 6980881
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of cleavage and inactivation of human serine protease inhibitors by the bacterial SPATE protease EspPα from enterohemorrhagic E. coli.
Weiss A; Joerss H; Brockmeyer J
PLoS One; 2014; 9(10):e111363. PubMed ID: 25347319
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the effects of snake venom proteinases on the activity of human plasma C1 esterase inhibitor, alpha 1-antichymotrypsin and alpha 2-antiplasmin.
Kress LF; Catanese J; Hirayama T
Biochim Biophys Acta; 1983 Jun; 745(2):113-20. PubMed ID: 6342681
[TBL] [Abstract][Full Text] [Related]
15. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase.
Shiryaev SA; Ratnikov BI; Chekanov AV; Sikora S; Rozanov DV; Godzik A; Wang J; Smith JW; Huang Z; Lindberg I; Samuel MA; Diamond MS; Strongin AY
Biochem J; 2006 Jan; 393(Pt 2):503-11. PubMed ID: 16229682
[TBL] [Abstract][Full Text] [Related]
16. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
17. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
18. Binding of a noncovalent inhibitor exploiting the S' region stabilizes the hepatitis C virus NS3 protease conformation in the absence of cofactor.
Gallo M; Pennestri M; Bottomley MJ; Barbato G; Eliseo T; Paci M; Narjes F; De Francesco R; Summa V; Koch U; Bazzo R; Cicero DO
J Mol Biol; 2009 Jan; 385(4):1142-55. PubMed ID: 19061898
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of human plasma serine proteinase inhibitors (serpins) by limited proteolysis of the reactive site loop with snake venom and bacterial metalloproteinases.
Kress LF
J Cell Biochem; 1986; 32(1):51-8. PubMed ID: 2429973
[TBL] [Abstract][Full Text] [Related]
20. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay.
Lin C; Rice CM
Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7622-6. PubMed ID: 7644466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
